We are a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics.
Our mission is to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.
We are singularly focused on developing an entirely new class of medicines that aims to be transformative for patients and their healthcare providers, turning targeted protein degradation into one of the most promising areas of medical research and challenging the perceived limits of drug discovery.
Our proprietary PROTACs, or proteolysis-targeting chimeras, are designed to work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
